BUSINESS COMBINATION - Narrative (Details) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		10 Months Ended	12 Months Ended
	Sep. 16, 2024 USD ($) contingentValueRight $ / shares	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2024 USD ($)
Business Combination [Line Items]
Selling, general and administrative expenses		$ 81,771	$ 52,821	$ 158,299	$ 100,842
Research and development expense		16,535	7,296	27,099	17,807
Alimera Sciences, Inc
Business Combination [Line Items]
Common Stock, par value (in dollars per share) | $ / shares	$ 0.01
Cash consideration per share (in dollars per share) | $ / shares	$ 5.50
Business combination, number of contingent value rights to be received | contingentValueRight	1
Repayment of Alimera Debt	$ 78,540
Payment of Alimera transaction costs	20,172
Payment of settlement of acquiree's equity awards	19,300
Cash paid at closing for settlement of equity awards	1,300
Cash settlement for pre-acquisition equity awards	9,535
Selling, general and administrative expenses							$ 8,800
Research and development expense							1,000
Fair value of CVRs	8,322
Business combination, contingent value rights	$ 8,700
Goodwill, Measurement Period Adjustment				109		$ 109
Payment of Alimera transaction costs		$ 200	$ 3,500	$ 1,100	$ 3,500
Alimera Sciences, Inc | Contingent Value Right
Business Combination [Line Items]
Selling, general and administrative expenses							$ 400